Concepedia

PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors

Mónica Tang, Rachel O’Connell, Frédéric Amant, Philip Beale, Orla McNally, Katrin Marie Sjoquist, Peter Grant, Alison Davis, Peter Sykes, Linda Mileshkin,

Gynecologic Oncology · 2019 · 88 citations · 33 references

DOIFull text

Open access

Concepts

References

33

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

, , +14

The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory

Robert J. Kurman, Ie‐Ming Shih · The American Journal of Surgical Pathology · 2010 · 1.8K citations · Full text

, , +17

Mutations in BRAF and KRAS Characterize the Development of Low-Grade Ovarian Serous Carcinoma

Gad Singer, Robert F. Oldt, Yoram Cohen et al. · JNCI Journal of the National Cancer Institute · 2003 · 852 citations

, , +17

Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)

Gordon John Sampson Rustin, Ignace Vergote, Elizabeth A. Eisenhauer et al. · International Journal of Gynecological Cancer · 2011 · 619 citations

, , +17

Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study

John Farley, William E. Brady, Vinod Vathipadiekal et al. · The Lancet Oncology · 2012 · 413 citations

, , +12